Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alkermes plc (NASDAQ: ALKS).

Full DD Report for ALKS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALKS)

Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
DUBLIN , Sept. 5, 2018 /PRNewswire/ --  Alkermes plc  (Nasdaq: ALKS) today announced that the company is now accepting applications for the 3 rd  annual ALKERMES INSPIRATION GRANTS ®  program. The competitive program will award up to $1 million in grants to vari...
Source: PR Newswire
Date: September, 05 2018 07:00
FDA updates on multifaceted plan to combat opioid crisis
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:44
FDA clamps down on opioid-peddling websites
The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc...
Source: SeekingAlpha
Date: August, 28 2018 10:57
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
Oklahoma first state to negotiate efficacy-based drug prices
Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD...
Source: SeekingAlpha
Date: August, 23 2018 10:54
FDA awards contract to develop guidelines for opioid prescribing
The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND...
Source: SeekingAlpha
Date: August, 22 2018 11:16
Catalyst-Rich Months Ahead For The Alkermes Pipeline
Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig...
Source: SeekingAlpha
Date: August, 17 2018 14:59
White House proposing cuts in opioid production
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &...
Source: SeekingAlpha
Date: August, 16 2018 15:24
Investors shun healthcare stocks in broad market selloff
Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc...
Source: SeekingAlpha
Date: August, 15 2018 10:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0842.8940.6942.94540.61795,857
2018-05-1747.5646.0147.6745.44822,854
2017-02-0355.4354.9555.4353.895630,091
2017-02-0254.5655.2355.4853.69805,474
2017-02-0154.4554.7054.9652.791,268,003

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1776,801310,73124.7162Cover
2018-12-14124,369426,73629.1442Cover
2018-12-13103,506254,39640.6870Short
2018-12-1248,955252,48119.3896Cover
2018-12-1145,439250,73418.1224Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALKS.


About Alkermes plc (NASDAQ: ALKS)

Logo for Alkermes plc (NASDAQ: ALKS)

Not available

 

Contact Information

 

 

Current Management

  • Richard F. Pops / CEO
  • Robert A. Breyer / President, COO
  • Michael J. Landine / CFO

Current Share Structure

  • Market Cap: $7,292,980,464 - 05/14/2018
  • Issue and Outstanding: 155,037,850 - 04/20/2018

 


Recent Filings from (NASDAQ: ALKS)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 19 2018

 

 


Daily Technical Chart for (NASDAQ: ALKS)

Daily Technical Chart for (NASDAQ: ALKS)


Stay tuned for daily updates and more on (NASDAQ: ALKS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALKS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALKS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALKS and does not buy, sell, or trade any shares of ALKS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/